Skip to content

Early Life Anemia and Children's Risk of Neurodevelopmental Disorders: National and Regional Register-based Studies

Early Life Anemia and Children's Risk of Neurodevelopmental Disorders: National and Regional Register-based Studies

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06199362
Enrollment
2400000
Registered
2024-01-10
Start date
2023-08-15
Completion date
2024-12-31
Last updated
2024-01-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ADHD, Anemia, Autism, Intellectual Disability, Neurodevelopmental Disorders

Brief summary

The overall project aim is to study children's neurodevelopmental outcomes (including diagnoses of autism, ADHD, and intellectual disability) following exposure to maternal anemia during pregnancy or anemia during the first year of life using national and regional Swedish health-data registers, and to assess children's neurodevelopmental outcomes over the range of maternal hemoglobin levels during pregnancy.

Detailed description

Our overall hypothesis is that early life iron sufficiency may promote appropriate neurodevelopment and reduce risk of neurodevelopmental disorders in children. We will use Swedish register data to define a cohort of maternal-child pairs to follow from gestation through childhood. We will consider exposure to anemia during two key time periods: gestation and the first year of life. Exposure data are recorded in Swedish medical records prospectively relative to the follow-up for the outcomes. To assess exposure to maternal anemia, we will consider maternal diagnoses of anemia during pregnancy in a national cohort of maternal-child pairs, using ICD codes recorded in pregnancy in the Swedish National Patient Register and the Swedish Medical Birth Register. In a sub-sample of mother-child pairs in Stockholm with data available from antenatal records (i.e., Obstetrix register data), we will also collect data regarding levels of maternal hemoglobin measured longitudinally over the course of pregnancy, and consider this as a continuous variable and divided into categories to reflect the full range of potential exposures from very low to very high. We will consider whether risk of the outcomes associated with exposure to anemia or decreasing hemoglobin levels vary with the time of onset during pregnancy. To assess exposure to anemia during the first year of life, we will consider infant's diagnoses of anemia during the first year of life in a national cohort of maternal-child pairs, using ICD codes recorded during the year after birth in the Swedish National Patient Register. We will consider whether risk of the outcomes associated with exposure to anemia during vary with the time of onset during the first year of life, and whether anemia during the first year interacts with gestational age at birth. The main outcome measures will be incidence of children's diagnoses of any of three common neurodevelopmental conditions: autism, attention-deficit/hyperactivity disorder (ADHD), and intellectual disability. Diagnoses will be ascertained using ICD codes recorded in pregnancy in the Swedish National Patient Register. For the sub-sample of mother-child pairs for children born in Stockholm, we will also ascertain outcomes in regional registers that capture further sources of outpatient treatment and care, primarily the VAL database. Secondary analyses will consider the incidence of commonly co-occurring combinations of the disorders (e.g., autism with co-occurring intellectual disability).

Interventions

None listed

Sponsors

The Swedish Research Council
CollaboratorOTHER_GOV
Karolinska Institutet
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
2 Years to 18 Years
Healthy volunteers
Yes

Inclusion criteria

* children born in Sweden from January 1, 1987 to December 31, 2010 (national cohort) * children born in Region Stockholm from January 1, 2007 to December 31, 2010 (Stockholm regional cohort)

Exclusion criteria

* Adopted children * Children without records in the Medical Birth Registry (MBR)

Design outcomes

Primary

MeasureTime frameDescription
AutismChildren's diagnoses of autism, with follow up beginning at 2 years of age.ICD-9: 299; ICD-10: F84
ADHDChildren's diagnoses of ADHD, with follow up beginning at 2 years of age.ICD-9: 314; ICD-10: F90; supplemented with methylphenidate \[N06BA04\] or atomoxetin \[N06BA09\] prescriptions registered in the Swedish Prescribed Drug Register
Intellectual DisabilityChildren's diagnoses of intellectual disability, with follow up beginning at 2 years of age.ICD-9: 317-319 ICD-10: F70-F79
Any Neurodevelopmental ConditionChildren's diagnoses of neurodevelopmental conditions, with follow up beginning at 2 years of age.Any diagnosis of Autism, ADHD, or Intellectual Disability

Secondary

MeasureTime frameDescription
Autism with Intellectual DisabilityChildren's diagnoses, with follow up beginning at 2 years of age.Diagnosis of both autism and intellectual disability during the follow-up period.
Intellectual Disability without AutismChildren's diagnoses, with follow up beginning at 2 years of age.Diagnosis of intellectual disability without a diagnosis of autism during the follow-up period.
Autism with ADHDChildren's diagnoses, with follow up beginning at 2 years of age.Diagnosis of both autism and ADHD during the follow-up period.
Autism without co-morbidities (ADHD or ID)Children's diagnoses, with follow up beginning at 2 years of age.Diagnosis of autism without a diagnosis of ADHD or intellectual disability during the follow-up period.
ADHD without co-morbidities (ID or Autism)Children's diagnoses, with follow up beginning at 2 years of age.Diagnosis of ADHD without a diagnosis of autism or intellectual disability during the follow-up period.

Countries

Sweden

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026